Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
JPM 2024
Biotech
ReCode CEO Shehnaaz Suliman eyes second half IPO opportunity
As green shoots slowly push from the biotech markets, ReCode CEO Shehnaaz Suliman, M.D., is watching closely, biding her time for a potential H2 IPO.
Annalee Armstrong
Jan 17, 2024 10:31am
Biotech investors tip toe around the bear to familiar bets
Jan 16, 2024 6:00am
Editor’s Corner: Driverless cars and doorless planes at JPM24
Jan 12, 2024 11:02am
JPM24: Roche's pharma BD chief explains renewed ADC interest
Jan 12, 2024 10:56am
JPM24: Roivant CEO has ‘pangs of regret’ for letting Telavant go
Jan 12, 2024 10:30am
JPM24: PacBio puts up 56% annual growth
Jan 11, 2024 11:52am
